
MetLife (MET) Stock Forecast & Price Target
MetLife (MET) Analyst Ratings
Bulls say
MetLife is attractive because its valuation remains below higher-rated life insurers even after a ~23% YTD rally, suggesting the market may still underappreciate its strategic execution and improving business mix. Its capital-light franchises—Group Benefits, Latin America, EMEA, and MetLife Investment Management—support high free cash flow and a 17% ROE in 2Q’26, with Group Benefits’ broad product suite and high-90% persistency reinforcing durable earnings. Further upside comes from leadership in Latin America and steadier variable investment income around $1.6 billion, while the U.S. businesses and rising rates should help sustain earnings and support a re-rating.
Bears say
MetLife is viewed negatively because its earnings are exposed to several volatile drivers, including interest rates, credit spreads, market-sensitive alternative investments, and pension risk transfer activity, which can create cash flow and liability instability. Although the stock appears inexpensive at about 9.6x 2026E P/E and 8.8x 2027E P/E versus peers at 10.3x and 9.3x, that valuation is tempered by the risk that favorable mortality and recent investment tailwinds may normalize or reverse. Competition across group benefits, RIS, Asia, Latin America, EMEA, and investment management, plus geopolitical exposure in international regions, could compress fees and margins and weigh on 2025 and 2024 earnings contributions.
This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.
MetLife (MET) Analyst Forecast & Price Prediction
Start investing in MetLife (MET)
Order type
Buy in
Order amount
Est. shares
0 shares